消费者用药依从行为探析：基于两阶段理论模型

doi:10.3724/SP.J.1042.2024.00859

摘要/Abstract

摘要： 个体健康行为改变是否存在阶段性是当前争议的焦点。用药依从行为作为关键的影响医疗效果指标, 对个体的身心健康产生重要影响。前人对于用药依从水平的研究综述大多是从医学角度, 着眼于特定疾病的用药依从行为。然而, 在医疗保健行业市场化的背景下, 鲜有研究从消费者的视角出发, 探究信息加工方式和心理过程对消费者用药依从行为的影响。同时, 现有研究也缺乏对依从行为的理论分类和论述。基于两阶段理论模型回顾了营销领域影响消费者用药依从行为的影响因素, 梳理了干预策略, 并提出未来研究趋势与展望。在理论上, 这有助于从健康行为改变阶段上理解个体的用药依从行为, 丰富健康领域的阶段理论。在实践上有助于更好地理解消费者的心理健康和行为规律, 并为慢性病管理提供了营销方面的启示。

关键词: 用药依从, 消费者行为, 医疗保健, 行为干预

Abstract: Current debates are centered on the controversial question of whether individual health behavior changes occur in stages. Medication adherence, a crucial indicator influencing medical outcomes, significantly impacts the physical and mental health of individuals. Medication adherence refers to the extent to which consumers follow or adopt recommendations from individuals or organizations regarding acquiring (purchasing) and correctly using medications. This includes both prescription and over-the-counter drugs, as well as products or services related to physical health examinations. Previous studies on medication adherence levels have predominantly taken a medical perspective, focusing on adherence behaviors for specific diseases. However, with the increasing marketization of the health care industry, limited research exists from the consumer's perspective investigating the influence of information processing and psychological processes on consumer medication adherence behaviors.
Current research indicates a growing emphasis on the stage theory of health behavior change for studying and promoting health. Derived from social cognitive theory, stage theory posits that consumer health behavior is not a continuous process but rather a multistage process. Individuals go through inherently different ordered stages in deciding, initiating, and maintaining health-related behaviors. Individuals within the same stage face common obstacles, while those in different stages encounter distinct challenges. In medication adherence research, the health action process theory has demonstrated significant advantages in operability, intervention assessment, and cultural and environmental adaptability. This theory divides the process of changing health behavior into two stages: motivation and volition. In the context of medication adherence, these stages align well with the awareness stage of drug acquisition and the trial and adoption stage of drug usage, offering a comprehensive summary of consumer medication adherence behaviors in these stages. This theory is intuitive and conducive to the targeted design of intervention measures. Therefore, this study is grounded in the two-stage theory of the health action process model, systematically reviewing and summarizing consumer medication adherence behaviors in the identified stages.
Building upon the health action process theory, this paper categorizes the consumer's medication adherence process into the awareness stage and the trial and adoption stage. In the awareness stage, factors influencing consumer medication adherence, such as inherent beliefs, prior knowledge of medications, and information processing biases, are summarized through a review of past research. In the trial and adoption stage, factors affecting consumer medication adherence, including the effectiveness rate of medication, marketing communication of medications, and after-sales services, are systematically summarized. After the factors influencing medication adherence levels were clarified, this paper further investigates each stage, delineating and elaborating on interventions for consumer medication adherence. The medication awareness stage involves attitude intervention, while the medication trial and adoption stage focus on behavior intervention. Central to attitude intervention is increasing medication willingness, a crucial factor in promoting the initial level of medication adherence. This paper outlines intervention strategies from three perspectives: customer education, enterprise nudging, and media regulation. According to two-stage theory, the focus of intervention in the medication trial and adoption stage is to prolong consumers' will in this stage by increasing medication willingness, thus sustaining medication adherence. Enhancing consumer medication adherence at the behavioral level requires joint efforts from consumers, enterprises, and relevant government health service departments. Combining the review literature, this paper systematically outlines intervention strategies for the medication trial and adoption stage from three aspects: customer empowerment, enterprise incentives, and multiparty collaboration. In the future, this paper proposes several prospects, including exploring the gap between “intention‒behavior,” adopting an integrated approach to investigate the complete process of medication adherence behavior, exploring prefactors influencing medication adherence behavior from a diverse perspective, and delving into the intrinsic mechanisms and influencing factors of (non)adherence to medication.
In conclusion, nonadherence or low adherence has become a significant constraint on consumer health. This paper, based on the two-stage theory model, integrates the influencing factors of adherence behaviors in these two stages and proposes corresponding intervention measures to promote domestic research development in this field. This study aims to overcome the current fragmented nature of related research by constructing a two-stage integrated model based on the two-stage model of health behavior change, considering both the acquisition and usage stages of medications, and building an integrated model from cognitive and treatment perspectives. Possible contributions include: (1) providing a two-stage integrated model based on the concept and definition of medication adherence, revealing influencing factors of medication adherence behaviors, summarizing intervention strategies for consumer medication adherence, and proposing future research trends and prospects, contributing to exploring, understanding, and intervening in individual medication adherence behaviors from the perspective of health behavior change stages; (2) stepping out of the traditional medical theoretical framework and delving into the consumer group and consumer psychology perspective, revealing the research dynamics and progress of medication adherence behaviors in the consumer behavior domain; (3) advancing and enriching stage theories in the health domain, as researchers in the health field hold inconsistent views on whether behavior is staged or nonstaged. This study categorizes the influencing factors and intervention strategies of medication adherence behaviors in different stages of health behavior change, contributing to advancing and enriching stage theories on health behavior; (4) This study holds significant practical significance. The COVID-19 pandemic has posed a significant threat to the lives and health of people worldwide, sounding an alarm for health behavior. This study contributes to understanding consumer behavior in the postpandemic stage and provides marketing insights for chronic disease management.

Key words: medication adherence, consumer behavior, health care, behavioral intervention

沈曼琼, 廖建财, 王海忠. (2024). 消费者用药依从行为探析：基于两阶段理论模型. 心理科学进展 , 32(5), 859-872.

SHEN Manqiong, LIAO Jiancai, WANG Haizhong. (2024). Analysis of consumer medication adherence: Based on two-stage theoretical model. Advances in Psychological Science, 32(5), 859-872.

参考文献

[1] 高雯, 杨丽珠, 李晓溪. (2012). 健康行动过程取向模型的发展与前景.心理科学进展, 20(10), 1651-1662.
[2] Ajzen, I. (1991). The theory of planned behavior.Organizational Behavior and Human Decision Processes, 50, 179-211.
[3] Agarwal R., Dugas M., Gao G. G., & Kannan P. K. (2020). Emerging technologies and analytics for a new era of value-centered marketing in healthcare. Journal of the Academy of Marketing Science, 48(1), 1-15.
[4] Agrawal N., Menon G., & Aaker J. L. (2007). Getting emotional about health.Journal of Marketing Research, 44(1), 100-113.
[5] Batra R. K., Brunel F., & Chandran S. (2009). When good looks kill: An examination of consumer response to visually attractive product design.Advances in Consumer Research, 36, 698-698.
[6] Bolton L. E., Reed A., Volpp K. G., & Armstrong K. (2008). How does drug and supplement marketing affect a healthy lifestyle?.Journal of Consumer Research, 34(5), 713-726.
[7] Bowman D., Heilman C. M., & Seetharaman P. B. (2004). Determinants of product-use compliance behavior.Journal of Marketing Research, 41(3), 324-338.
[8] Brieger W. R., Salami K. K., & Oshiname F. O. (2007). Perceptions of drug color among drug sellers and consumers in rural southwestern Nigeria.Research in Social and Administrative Pharmacy, 3(3), 303-319.
[9] Briley D. A., Melanie R., & Jennifer A. (2017). Cultivating optimism: How to frame your future during a health challenge. Journal of Consumer Research, 44(4), 895-915.
[10] Brug J., Conner M., Harre N., Kremers S., McKellar S., & Whitelaw S. (2005). The Transtheoretical Model and stages of change: A critique: Observations by five commentators on the paper by Adams, J. and White, M.(2004) why don't stage-based activity promotion interventions work?.Health Education Research, 20(2), 244-258.
[11] Camacho N., De Jong M., & Stremersch S. (2014). The effect of customer empowerment on adherence to expert advice. International Journal of Research in Marketing, 31(3), 293-308.
[12] Chandran, S., & Menon, G. (2004). When a day means more than a year: Effects of temporal framing on judgments of health risk.Journal of Consumer Research, 31(2), 375-389.
[13] Christensen CM. Grossman J, Hwang J. (2009). The Innovator's Prescription (p. 161). New York: McGraw-Hill.
[14] Conner M., McEachan R., Jackson C., McMillan B., Woolridge M., & Lawton R. (2013). Moderating effect of socioeconomic status on the relationship between health cognitions and behaviors.Annals of Behavioral Medicine, 46(1), 19-30.
[15] Conner M.,& Sparks, P. (2005). The theory of planned behaviour and health behaviours. In M. Conner & P. Norman (Eds.), Predicting health behaviour: Research and practice with social cognition models (2nd ed., pp. 170-222). Maidenhead, England: Open University Press.
[16] Cox A. D., Cox D., & Zimet G. (2006). Understanding consumer responses to product risk information.Journal of Marketing, 70(1), 79-91.
[17] Cutler R. L., Fernandez-Llimos F., Frommer M., Benrimoj C., & Garcia-Cardenas V. (2018). Economic impact of medication non- adherence by disease groups: A systematic review.British Medical Journal Open, 8(1), e016982.
[18] de Bruin M., Sheeran P., Kok G., Hiemstra A., Prins J. M., Hospers H. J., & van Breukelen, G. J. (2012). Self-regulatory processes mediate the intention-behavior relation for adherence and exercise behaviors.Health Psychology, 31(6), 695-703.
[19] Dellande S., Gilly M. C., & Graham J. L. (2004). Gaining compliance and losing weight: The role of the service provider in health care services.Journal of Marketing, 68(3), 78-91.
[20] Desai N. R., Ross J. S., Kwon J. Y., Herrin J., Dharmarajan K., & Bernheim S. M., et al. (2016). Association between hospital penalty status under the hospital readmission reduction program and readmission rates for target and nontarget conditions.JAMA, 316(24), 2647-2656.
[21] Fallis B. A., Dhalla I. A., Klemensberg J., & Bell C. M. (2013). Primary medication non-adherence after discharge from a general internal medicine service.PloS One, 8(5), e61735.
[22] Fischer M. A., Choudhry N. K., Bykov K., Brill G., Bopp G., Wurst A. M., & Shrank W. H. (2014). Pharmacy- based interventions to reduce primary medication nonadherence to cardiovascular medications.Medical Care, 52(12), 1050-1054.
[23] Gerend, M. A., & Maner, J. K. (2011). Fear, anger, fruits, and veggies: Interactive effects of emotion and message framing on health behavior.Health Psychology, 30(4), 420-423.
[24] Gershoff, A. D., & Koehler, J. J. (2011). Safety first? The role of emotion in safety product betrayal aversion.Journal of Consumer Research, 38(1), 140-150.
[25] Giuffrida, A., & Torgerson, D. J. (1997). Should we pay the patient? Review of financial incentives to enhance patient compliance.BMJ, 315(7110), 703-707.
[26] Glanz K., Rimer B. K., & Viswanath K. (2008). Health behavior and health education: Theory, research, and practice (pp. 23-40). Jossey-Bass.
[27] Griffith J. M., Lewis C. L., Pignone M. P., Sheridan S. L., & Hawley S. (2009). Randomized trial of presenting absolute v. relative risk reduction in the elicitation of patient values for heart disease prevention with conjoint analysis.Medical Decision Making, 29(2), 167-174.
[28] Hackerson M. L., Luder H. R., Beck A. F., Wedig J. M., Heaton P. C., & Frede S. M. (2018). Addressing primary nonadherence: A collaboration between a community pharmacy and a large pediatric clinic.Journal of the American Pharmacists Association, 58(4), S101-S108.
[29] Hatzenbuehler M. L., Phelan J. C., & Link B. G. (2013). Stigma as a fundamental cause of population health inequalities.American Journal of Public Health, 103(5), 813-821.
[30] Hassan, A., & Barber, S. J. (2021). The effects of repetition frequency on the illusory truth effect.Cognitive Research: Principles and Implications, 6(1), 1-12.
[31] Hastings T. J., Hohmann N. S., Jeminiwa R., Hansen R. A., Qian J., & Garza K. B. (2021). Perceived appropriateness of medication adherence incentives.Journal of Managed Care & Specialty Pharmacy, 27(6), 772-778.
[32] Hausman, A. (2004). Modeling the patient-physician service encounter: Improving patient outcomes.Journal of the Academy of Marketing Science, 32(4), 403-417.
[33] Hernandez-Tejada M. A., Campbell J. A., Walker R. J., Smalls B. L., Davis K. S., & Egede L. E. (2012). Diabetes empowerment, medication adherence and self-care behaviors in adults with type 2 diabetes.Diabetes Technology & Therapeutics, 14(7), 630-634.
[34] Ilyuk V., Block L., & Faro D. (2014). Is it still working? Task difficulty promotes a rapid wear-off bias in judgments of pharmacological products.Journal of Consumer Research, 41(3), 775-793.
[35] Ilyuk, V., & Block, L. (2016). The effects of single-serve packaging on consumption closure and judgments of product efficacy.Journal of Consumer Research, 42(6), 858-878.
[36] Ilyuk V., Irmak C., Kramer T., & Block L. (2014). Efficacy expectations and adherence: Evidence of consumer biases and heuristics in pharmaceutical marketing. In D. Min, J. Eliashberg, & S. Stremersch,(Eds.), Innovation & marketing in the pharmaceutical industry
[37] Kaplan, R. M., & Milstein, A. (2021). Influence of a covid-19 vaccine's effectiveness and safety profile on vaccination acceptance.Proceedings of the National Academy of Sciences, 118(10), e2021726118.
[38] Kardes, F. R., & Cronley, P. M. L. (2004). Consumer inference: A review of processes, bases, and judgment contexts.Journal of Consumer Psychology, 14(3), 230-256.
[39] Kramer T., Irmak C., Block L. G., & Ilyuk V. (2012). The effect of a no-pain, no-gain lay theory on product efficacy perceptions.Marketing Letters, 23(3), 517-529.
[40] Lee S. Y., Hwang H., Hawkins R., & Pingree S. (2008). Interplay of negative emotion and health self-efficacy on the use of health information and its outcomes.Communication Research, 35(3), 358-381.
[41] Mead J.,A. Richerson,R. (2018). Package color saturation and food healthfulness perceptions.Journal of Business Research, 82, 10-18.
[42] Mourali, M., & Yang, Z. (2023). Misperception of multiple risks in medical decision-making.Journal of Consumer Research, 50(1), 25-47.
[43] Nielsen-Bohlman, L., Panzer, A. M., & Kindig, D. A. (2004). The extent and associations of limited health literacy. In Health literacy: A prescription to end confusion (Chapter 3, pp. 59-70). National Academies Press (US).
[44] Noordraven E. L., Wierdsma A. I., Blanken P., Bloemendaal A. F., Staring A. B., & Mulder C. L. (2017). Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): A multicentre, open-label, randomised controlled trial.The Lancet Psychiatry, 4(3), 199-207.
[45] Prochaska, J. O., & DiClemente, C. C. (1983). Stages and processes of self-change of smoking: Toward an integrative model of change.Journal of Consulting and Clinical Psychology, 51(3), 390-395.
[46] Reuter T., Ziegelmann J. P., Wiedemann A. U., Lippke S., Schüz B., & Aiken L. S. (2010). Planning bridges the intention-behaviour gap: Age makes a difference and strategy use explains why. Psychology and Health, 25(7), 873-887.
[47] Rich A., Brandes K., Mullan B., & Hagger M. S. (2015). Theory of planned behavior and adherence in chronic illness: A meta-analysis. Journal of Behavioral Medicine, 38, 673-688.
[48] Rogers, R. W. (1983). Cognitive and physiological processes in fear appeals and attitude change: A revised theory of protection motivation. In B. L. Cacioppo & L. L. Petty (Eds.), Social psychophysiology: A sourcebook (pp. 153-176). London, England: Guildford.
[49] Roullet, B., & Droulers, O. (2005). Pharmaceutical packaging color and drug expectancy. Paper presented at the meeting of the Association for Consumer Research, San Antonio, Texas.
[50] Samper, A., & Schwartz, J. A. (2013). Price inferences for sacred versus secular goods: Changing the price of medicine influences perceived health risk.Journal of Consumer Research, 39(6), 1343-1358.
[51] Santo K., Singleton A., Rogers K., Thiagalingam A., Chalmers J., Chow C. K., & Redfern J. (2019). Medication reminder applications to improve adherence in coronary heart disease: A randomised clinical trial.Heart, 105(4), 323-329.
[52] Scholz U., Klaghofer R., Dux R., Roellin M., Boehler A., Muellhaupt B., .. Goetzmann L. (2012). Predicting intentions and adherence behavior in the context of organ transplantation: Gender differences of provided social support. Journal of Psychosomatic Research, 72(3), 214-219.
[53] Schüz B., Sniehotta F. F., & Schwarzer R. (2007). Stage-specific effects of an action control intervention on dental flossing.Health Education Research, 22(3), 332-341.
[54] Schüz B., Sniehotta F. F., Mallach N., Wiedemann A. U., & Schwarzer R. (2009). Predicting transitions from preintentional, intentional and actional stages of change.Health Education Research, 24(1), 64-75.
[55] Schwarzer, R., & Luszczynska, A. (2008). How to overcome health-compromising behaviors: The health action process approach.European Psychologist, 13(2), 141-151.
[56] Schwarzer R.,& Luszczynska, A. (2005). Social cognitive theory. In M. Conner, & P. Norman (Eds.), Predicting Health Behaviour (2nd Ed., pp. 127-169). Buckingham, UK: Open University Press.
[57] Schwarzer, R. (2008a). Modeling health behavior change: How to predict and modify the adoption and maintenance of health behaviors.Applied Psychology, 57(1), 1-29.
[58] Schwarzer, R. (2008b). Some burning issues in research on health behavior change.Applied Psychology: An International Review, 57(1), 84-93.
[59] Seiders K., Flynn A. G., Berry L. L., & Haws K. L. (2015). Motivating customers to adhere to expert advice in professional services: A medical service context. Journal of Service Research, 18(1), 39-58.
[60] Sheeran, P. (2002). Intention—behavior relations: A conceptual and empirical review.European Review of Social Psychology, 12(1), 1-36.
[61] Sheeran, P., & Abraham, C. (2003). Mediator of moderators: Temporal stability of intention and the intention-behavior relation.Personality and Social Psychology Bulletin, 29(2), 205-215.
[62] Shen M., Gao S., & Wang H. (2023). The effect of social crowding on self‐perceived health risks in healthcare services.Psychology & Marketing, 40(4), 845-862.
[63] Shi Z., Liu X., & Srinivasan K. (2022). Hype news diffusion and risk of misinformation: The Oz effect in health care.Journal of Marketing Research, 59(2), 327-352.
[64] Siegrist, M., & Árvai, J. (2020). Risk perception: Reflections on 40 years of research.Risk Analysis: An International Journal, 40(1), 2191-2206.
[65] Snell L., White L., & Dagger T. (2014). A socio-cognitive approach to customer adherence in health care.European Journal of Marketing, 48(3/4), 496-521.
[66] Song, H., & Schwarz, N. (2009). If it’s difficult to pronounce, it must be risky: Fluency, familiarity, and risk perception.Psychological Science, 20(2), 135-138.
[67] Steffel M., Williams E. F., & Carney S. (2022). Empowering consumers to engage with health decisions: Making medical choices feel easy increases patient participation.Journal of the Association for Consumer Research, 7(2), 154-163.
[68] Tabi K., Randhawa A. S., Choi F., Mithani Z., Albers F., Schnieder M., … Krausz M. (2019). Mobile apps for medication management: Review and analysis. JMIR MHealth and UHealth, 7(9), e13608.
[69] Tian M., Kaufman D. W., Shiffman S., & Arora N. (2023). EXPRESS: Over-the-counter drug consumption: How consumers deviate from label instructions.Journal of Marketing Research, doi: 10.1177/00222437231199434.
[70] Tversky, A., & Kahneman, D. (1974). Judgment under Uncertainty: Heuristics and Biases: Biases in judgments reveal some heuristics of thinking under uncertainty.Science, 185(4157), 1124-1131.
[71] Vervloet M., Linn A. J., van Weert J. C., De Bakker D. H., Bouvy M. L., & Van Dijk L. (2012). The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: A systematic review of the literature.Journal of the American Medical Informatics Association, 19(5), 696-704.
[72] Wang, H. S., & Yim, C. K. (2019). Effects of dominance transitions on advice adherence in professional service conversations.Journal of the Academy of marketing Science, 47(5), 919-938.
[73] Wang L., Touré-Tillery M., & McGill A. L. (2023). The effect of disease anthropomorphism on compliance with health recommendations.Journal of the Academy of Marketing Science, 51(2), 266-285.
[74] Wang P., Sun L., Zhang L., & Niraj R. (2021). Reference points in consumer choice models: A review and future research agenda.International Journal of Consumer Studies, 45(5), 985-1006.
[75] Wang W., Keh H. T., & Bolton L. E. (2010). Lay theories of medicine and a healthy lifestyle. Journal of Consumer Research, 37(1), 80-97.
[76] Weinstein, N. D. (1993). Testing four competing theories of health-protective behavior.Health Psychology, 12(4), 324-333.
[77] Weinstein N. D., Rothman A. J., & Sutton S. R. (1998). Stage theories of health behavior: Conceptual and methodological issues.Health Psychology, 17(3), 290-299.
[78] Wittkowski K., Klein J. F., Falk T., Schepers J. J., Aspara J., & Bergner K. N. (2020). What gets measured gets done: Can self-tracking technologies enhance advice compliance?.Journal of Service Research, 23(3), 281-298.
[79] Wosinska, M. (2005). Direct-to-consumer advertising and drug therapy compliance.Journal of Marketing Research, 42(3), 323-332.
[80] Yan, D., Sengupta, J. (2013). The influence of base rate and case information on health-risk perceptions: A Unified model of self-positivity and self-negativity.Journal of Consumer Research, 39(5), 931-946.